CD19 and neoplasm: Some targets for genetic engineering in NK cells are uniquely expressed in tumor-specific conditions, like Hypoxia-inducible factor 1 in hypoxic environments [66], while others, like CD38 or CD19, exhibit distinct glycosylation patterns in tumor cells compared to their normal counterparts [67].